Related Experiment Video
Updated: Jun 17, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Recent Advances in Intravesical Chemotherapy: Insights into the FDA-Approved Gemcitabine-Releasing TAR-200 System for
Abhishek Sharma1, Aman Kumar1, Preeti Patel2
1Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga-142001, Punjab, India.
Abstract:
The FDA approval of the gemcitabine intravesical system (Inlexzo/TAR-200) marks a breakthrough for BCG-unresponsive NMIBC with CIS. This novel drug-device combination enables sustained intravesical chemotherapy, achieving high complete response rates with acceptable safety. It represents a paradigm shift in bladder-sparing therapy, though long-term outcomes and accessibility remain critical considerations.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
